BIERMAN JAMES L sold $1.2M of THC

BIERMAN JAMES L sold 5,000 shares of TENET HEALTHCARE CORP (THC) at $244.96 ($1.22M total) on 2026-07-27.

Original reporting
SEC EDGAR · BIERMAN JAMES L
Published Jul 29, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The newest fact is the specific sale size (5,000 shares), price ($244.96), and total proceeds ($1.2248M) reported in the Form 4.

02

Market read

Traders may monitor insider selling as a sentiment input, but the filing alone does not provide new fundamentals or guidance.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says no), nor does it provide context on total compensation, prior sales cadence, or remaining holdings beyond the post-transaction figure.

Relevance 6/10Novelty 5/10Timing: SEC Form 4 filed 2026-07-28 for a 2026-07-27 sale.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Tenet Healthcare director James L Bierman.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director James L Bierman filed a Form 4 selling 5,000 shares at $244.96 on 2026-07-27, totaling $1.2248M.

Expected impact

Likely limited near-term price impact; any effect is sentiment-driven and typically fades unless accompanied by other disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but it is an open-market sale with no 10b5-1 plan stated and no accompanying operational or guidance change in the text.

Market effects

No sector-level read-across provided; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-scheduled liquidity needs, so the signal may be weaker than headline sentiment suggests.

Key entities

  • TENET HEALTHCARE CORP

    Company whose director insider sale is disclosed on Form 4.

  • BIERMAN JAMES L

    Director who sold 5,000 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.